Is Somapacitan legal in the US?
Yes, FDA approved for growth hormone shortage in adults and children, and some short stature in children.
Somapacitan is FDA-approved as Sogroya (Novo Nordisk), a once-weekly injection, for adults with growth hormone deficiency (August 2020), children aged 2.5 and older with growth hormone deficiency (2023), and, since February 27, 2026, children aged 2.5 and older with idiopathic short stature, short stature after being born small for gestational age, or growth failure from Noonan syndrome. 23
No. It is approved for adults with diagnosed growth hormone deficiency, confirmed by stimulation testing. REAL 1 saw less trunk fat in people who lacked the hormone. Somapacitan trials in healthy adults give no evidence. The label warns against use without deficiency. 12
Read the full Somapacitan page
More on Somapacitan
Citations
- Johannsson 2020, J Clin Endocrinol Metab: once-weekly somapacitan vs daily GH in adults with GH deficiency (REAL 1) pubmed.ncbi.nlm.nih.gov
- Sogroya (somapacitan-beco) prescribing information, Novo Nordisk novo-pi.com
- HCPLive, Feb 2026: FDA approves three new pediatric indications for somapacitan (REAL8) hcplive.com
Reference information only, not medical advice. Drawn from the Somapacitan article, fact-checked against the cited sources. No dosing anywhere on this site.